PerspectiveBladder Cancer

Bladder Cancer: Optimal Application of Preclinical Models to Suitable Translational Questions

See allHide authors and affiliations

Science Translational Medicine  10 Mar 2010:
Vol. 2, Issue 22, pp. 22ps11
DOI: 10.1126/scitranslmed.3000215

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Bladder cancer is a paradigm of solid tumor malignancy, and despite increased understanding of the molecular biology of this disease, cure rates have not changed greatly for 20 years. Further progress is being slowed by poor accrual of patients to structured clinical trials. The use of preclinical models, and in particular bladder cancer xenografts and cell lines, may allow more rational design of clinical trials, provided that the experimental questions posed are within the capability of the respective models. With the availability of targeted therapeutic drugs for treating bladder cancer, these models may be useful for the design of drug combination regimens and optimal sequencing of reagents.


  • Citation: D. Raghavan, Bladder cancer: Optimal application of preclinical models to suitable translational questions. Sci. Transl. Med. 2, 22ps11 (2010).

View Full Text

Stay Connected to Science Translational Medicine